Patent intelligence · US
US 9375423
Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
Patent details — US 9375423
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 28, 2016
- Expiration
- Jun 23, 2036
- Applicant
- Asana BioSciences, LLC
- Claims
- 16
- CPC classes
- A61K, A61K31/015, A61K31/167, A61K31/40
Quick answer
US 9375423 (Use of aminoindane compounds in treating overactive bladder and interstitial cystitis) is held by Asana BioSciences, LLC. Status: granted. Granted Jun 28, 2016. Expires Jun 23, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/015, A61K31/167, A61K31/40, A61K31/435, A61K31/438
More from Asana BioSciences, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 9375423?
US 9375423 (Use of aminoindane compounds in treating overactive bladder and interstitial cystitis) is held by Asana BioSciences, LLC. Status: granted. Granted Jun 28, 2016. Expires Jun 23, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9375423?
Asana BioSciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 9375423 expire?
Our index shows an expiration date of Jun 23, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.